Novartis Wins Top Share Of HHS’ Initial Pandemic Flu Vaccine Contracts
Executive Summary
Three large companies will get the lion's share of the federal government's first $1 billion in spending on development of vaccine for the emerging novel strain of influenza
You may also be interested in...
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.
If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.
If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts
Start-Ups Set Sights on Flu
The swine flu/H1N1 pandemic presents a lucrative opportunity for drug developers and Big Pharmas won't be the only firms to capitalize on the sudden multibillion-dollar opportunity. There's evidence that the pandemic is driving investors to flu-focused biotechs as well. In this issue, we profile four emerging companies that hope to reap the rewards of what should continue to be a promising fund-raising environment for potentially novel flu therapies.